论文部分内容阅读
目的比较和评价含莫西沙星(MXFX)方案与含左氧氟沙星(LVFX)方案对老年耐多药肺结核病(MDR-PTB)的治疗效果及安全性。方法将70例老年痰菌阳性的MDR-PTB患者随机分成试验组(T组)35例与对照组(C组)35例,T组用12MDL2E方案;C组用12VDL2E方案。2组患者于治疗期间前6个月均加用乌体林斯,疗程结束时可评价疗效者T组31例、C组30例。结果治疗满2个月时痰菌阴转率T组为70.97%、C组为40.00%(P<0.05),3个月时分别为90.32%、60.00%(P<0.01);6个月后各期痰菌阴转率T组均大于C组,但差异无显著性(P>0.05);满疗程时2组病灶吸收好转率分别为87.10%、73.33%,空洞闭合率为分别20.00%、11.54%,2组对比差异无显著性(P>0.05)。副作用分别为22.86%、26.47%,差异无显著性(P>0.05)。结论莫西沙星对老年MDR-PTB的治疗是有效且安全的。
Objective To compare and evaluate the efficacy and safety of MXFX and levofloxacin (LVFX) in the treatment of MDR-PTB in the elderly. Methods Seventy patients with MDR-PTB were selected and randomly divided into 35 cases in trial group (group T) and 35 cases in control group (group C), 12MDL2E in group T and 12VDL2E in group C. Two groups of patients in the treatment of the first 6 months plus Wu Lin Linsi, treatment can be evaluated at the end of the efficacy of T group of 31 patients, C group of 30 patients. Results The sputum negative conversion rate was 70.97% in group T and 40.00% in group C (P <0.05) at 2 months after treatment, 90.32% and 60.00% respectively at 3 months (P <0.01). After 6 months The rates of sputum negative conversion in each group were higher than those in group C (P> 0.05). The rates of improvement in two groups were 87.10% and 73.33%, respectively, and the void closure rates were 20.00% and 20.00% 11.54%, there was no significant difference between the two groups (P> 0.05). The side effects were 22.86% and 26.47% respectively, with no significant difference (P> 0.05). Conclusion Moxifloxacin is effective and safe in the treatment of elderly MDR-PTB.